◀ Back to RAC1

RAC1 — SMN1

Text-mined interactions from Literome

Mondin et al., Biochem Pharmacol 2007 : Pharmacological inhibition of RhoA activity reduced expression of both SMA and calponin, whereas overexpression of a dominant negative form of Rac1 increased SMA expression ... Conversely, overexpression of constitutively active Rac1 resulted in SMA and b-calp down-regulation, and fully prevented their stimulation by MPA, indicating that Rac inactivation is responsible for MPA effects on mesangial cytoskeletal expression
Sebe et al., FEBS Lett 2008 : Dominant negative ( DN ) Rac , DN-PAK, DN-p38, or the p38 inhibitor SB203580 suppressed the LCM induced nuclear accumulation of MRTF and the activation of the SMA promoter
Fintha et al., Am J Pathol 2013 (Diabetic Nephropathies...) : When co-expressed, it inhibited the stimulatory effects of MRTF-A, MRTF-B or the constitutive active forms of RhoA, Rac1 , or Cdc42 on the SMA promoter